is among the top 3 of institutes in the area of environment and health research that collaborate most frequently in EU
projects, as was demonstrated by the WHO
report ‘Improving Environment and Health in Europe’. Our experts and researchers engage in collaborative research projects, and participate in advisory and expert panels. Of course an important part of the international collaboration takes place in the European context, but RIVM also has close ties with specialised agencies of the UN
, such as WHO
. Such centres as the European Reference Lab and the WHO
Collaborating Centres are housed at RIVM
, and bilateral cooperation takes place with relevant institutions in the USA
The Horizon 2020 programme of the European Commission is of key importance for the funding of RIVM's international collaboration. Horizon 2020 succeeds the Seventh Framework Programme and is the biggest EU Research and Innovation programme in Europe. Horizon 2020 stimulates research and innovation in the EU.
Horizon 2020 work programme comprises of several pillars and various thematic sections. RIVM is mainly involved in projects within the societal challenges, but our institute is also involved in projects in other pillars. Within the Societal Challenges RIVM focuses mainly on Health, Climate Action and Environment, Secure Societies, and Food Security.
Together with partners all over Europe, RIVM was involved in over 70 projects funded by the 7th Framework Programme for Research and Technological Development,
FP7. This EU
programme ran from 2007 until 2013 and awarded grants to co-finance research, technological development and demonstration projects. Grants ware determined on the basis of calls for proposals and a peer review process. RIVM
is still in progress with 11 projects.
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA. IMI launches a number of research and/or training projects every year. Project participants are recruited through open and competitive calls for research proposals. The selection of the winning proposals is based on independent peer review. RIVM is partner in several IMI financed projects.